CARsgen Therapeutics Holdings Limited (2171.HK)
HKD 8.83
(-0.56%)
HKD 8.83
(-0.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 455.51 Million CNY | 57.27% |
| 2022 | 289.64 Million CNY | -43.09% |
| 2021 | 508.97 Million CNY | -82.63% |
| 2020 | 2.92 Billion CNY | 176.83% |
| 2019 | 1.05 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 605.18 Million CNY | 0.0% |
| 2024 Q1 | 605.18 Million CNY | 32.86% |
| 2023 Q4 | 455.51 Million CNY | 0.0% |
| 2023 FY | 455.51 Million CNY | 57.27% |
| 2023 Q3 | 455.51 Million CNY | 3.68% |
| 2023 Q2 | 439.36 Million CNY | 0.0% |
| 2023 Q1 | 439.36 Million CNY | 51.69% |
| 2022 Q2 | 489.12 Million CNY | 0.0% |
| 2022 Q1 | 489.12 Million CNY | -3.9% |
| 2022 FY | 289.64 Million CNY | -43.09% |
| 2022 Q4 | 289.64 Million CNY | 0.0% |
| 2022 Q3 | 289.64 Million CNY | -40.78% |
| 2021 FY | 508.97 Million CNY | -82.63% |
| 2021 Q4 | 508.97 Million CNY | 0.0% |
| 2021 Q3 | 508.97 Million CNY | 21.16% |
| 2021 Q2 | 420.08 Million CNY | 0.0% |
| 2021 Q1 | 420.08 Million CNY | -85.66% |
| 2020 FY | 2.92 Billion CNY | 176.83% |
| 2020 Q4 | 2.92 Billion CNY | 0.0% |
| 2020 Q3 | 2.92 Billion CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2019 FY | 1.05 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -198.076% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 93.546% |